Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PASG Passage BIO Inc
- Stocks
- Healthcare
- NASDAQ: PASG
Price (delayed)
$0.483
Market cap
$30.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.02
Enterprise value
-$8.22M
Passage Bio, has the mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with
Highlights
The EPS has grown by 33% YoY and by 4.7% from the previous quarter
The net income is up by 25% year-on-year and by 2% since the previous quarter
The quick ratio has shrunk by 56% YoY and by 10% QoQ
The equity has plunged by 55% YoY and by 24% from the previous quarter
Key stats
What are the main financial stats of PASG
Market
Valuations
Earnings
Shares outstanding
62.15M
Market cap
$30.02M
Enterprise value
-$8.22M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$63.46M
Net income
-$63.46M
EBIT
-$63.46M
EBITDA
-$60.99M
Free cash flow
-$42.32M
Per share
Balance sheet
Liquidity
EPS
-$1.02
EPS diluted
-$1.02
Free cash flow per share
-$0.68
Book value per share
$0.75
Revenue per share
$0
TBVPS
$1.38
Total assets
$86.01M
Total liabilities
$39.3M
Debt
$25.12M
Equity
$46.71M
Working capital
$48.84M
Debt to equity
0.54
Current ratio
3.74
Quick ratio
3.55
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-59.6%
Return on equity
-93.6%
Return on invested capital
-83.6%
Return on capital employed
-93.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PASG stock price
How has the Passage BIO stock price performed over time
Intraday
-3.21%
1 week
34.24%
1 month
22.28%
1 year
-61.05%
YTD
-14.83%
QTD
36.79%
Financial performance
How have Passage BIO's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$63.46M
Net income
-$63.46M
Gross margin
N/A
Net margin
N/A
The net income is up by 25% year-on-year and by 2% since the previous quarter
The operating income is up by 25% year-on-year and by 2% since the previous quarter
Price vs fundamentals
How does PASG's price correlate with its fundamentals
Growth
What is Passage BIO's growth rate over time
Valuation
What is Passage BIO stock price valuation
P/E
N/A
P/B
0.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 33% YoY and by 4.7% from the previous quarter
The equity has plunged by 55% YoY and by 24% from the previous quarter
The stock's price to book (P/B) is 42% less than its 5-year quarterly average of 1.1 but 28% more than its last 4 quarters average of 0.5
Efficiency
How efficient is Passage BIO business performance
The ROIC has contracted by 41% YoY and by 26% from the previous quarter
The company's return on equity fell by 37% YoY and by 19% QoQ
PASG's return on assets is down by 16% year-on-year and by 10% since the previous quarter
Dividends
What is PASG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PASG.
Financial health
How did Passage BIO financials performed over time
Passage BIO's total assets is 119% more than its total liabilities
Passage BIO's current ratio has plunged by 56% YoY and by 8% from the previous quarter
The quick ratio has shrunk by 56% YoY and by 10% QoQ
The debt is 46% less than the equity
The debt to equity has soared by 116% YoY and by 29% from the previous quarter
The equity has plunged by 55% YoY and by 24% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.